Coronavirus: China at risk of a winter spike in infections, experts say
- Beijing is under pressure to control both regional outbreaks and imported cases, says Wu Zunyou, chief epidemiologist at the Chinese Centre for Disease Control and Prevention
- Covid-19 pandemic likely to continue through the spring, respiratory disease expert Zhong Nanshan says
Wu Zunyou, chief epidemiologist at the Chinese Centre for Disease Control and Prevention (CDC), said the country had already experienced four waves of infections and a fifth was possible.
“Except for the initial outbreak in Wuhan, the outbreaks were sporadic, regional cases and they were effectively controlled,” he said.
Beijing was now under pressure to control both regional outbreaks and imported cases, Wu said.
The isolation of asymptomatic cases and contact tracing were important and effective measures to contain the spread of the virus, he said, adding that nucleic acid tests would be more widely used to detect cases at an early stage.
Other epidemiologists have also stressed the need for strong prevention and control measures this winter.
China would continue to carry out nucleic acid tests, trace close contacts and isolate asymptomatic patients if another domestic outbreak emerged, he said.
Since the health crisis began at the end of last year, more than 30 million coronavirus infections have been reported around the world and almost 950,000 people have lost their lives to Covid-19.
Case numbers have surged in several European countries recently, raising concerns about a possible spike this winter.
A total of 300,000 new infections were reported across Europe last week, which was more than the previous high seen in March, he said.
“Although these numbers reflect more comprehensive testing, it also shows alarming rates of transmission across the region,” he said.
Meanwhile, China’s CDC said this week that some Chinese cities would be offering flu shots a month earlier than normal to help reduce the risk of dual infections.
“The vaccines can reduce the occurrence of pneumonia and influenza so that it can reduce the demand and difficulty of diagnosis of Covid-19,” Wu said.
The results of the phase three trials of China’s Covid-19 vaccine candidates would be available by the end of the year, he said.